Wednesday, January 11, 2023 2:07:56 PM
I am writing today to clarify the appropriate positioning of medications known as OMEGA -3. These medications are often called “fish oil” by people without adequate knowledge. It is important to realize that there are many types of Omega 3 oils but for our purposes we need to only discuss two, DHA and EPA. There are significant differences in how each of these substance react at the biochemical level within the human body. I will not delve into this, for brevity's sake, but suffice it to say that EPA substantially reduces inflammation.
Lovaza (and generic Lovaza) contains DHA and EPA. Lovaza (and its generic) is only approved to reduce triglycerides over 500mg/dl . Lovaza actually increases LDL by a whopping 49%. It is theorized that this is a result of the DHA component.
Vascepa is pure EPA (Isocapent ethyl). In a landmark study called REDUCE IT – Coronary events were reduced by a substantial 25% in individuals already on statins who were prescribed Vascepa . (The reduction would have probably been much more on individuals not taking statins ) Recent analysis of data also suggests CVA reduction by 30% . It is theorized that EPA is achieving this by reduction of inflammation.
Appropriate classification and positioning of Omega 3 medications.
Lovaza (L) and Generic Lovaza (gL)
These are a combinations of EPA and DHA. The only appropriate utilization is for triglycerides > 500 to prevent pancreatitis. You should note that if you have this listed under CARDIOVASCULAR DRUGS – antilipemics ( as you also may have listed fibrates / niacin etc.) that NONE of these drugs have any outcomes study showing any improvement in Cardiovascular outcomes!. The only possible use of these medications is the reduction of triglycerides > 500 for the prevention of pancreatitis. Lovaza may actually induce cardiovascular disease since it increases LDL by 49%. These medications should NOT be listed as cardiovascular medicines.
Vascepa (V) and Generic Vascepa (gV)
These medications contain only EPA – both of these medication can be utilized for Trigs >500mg/dl, however, the fact of the matter is Lovaza (DHA /EPA) works better for pure trig reduction.
The vast majority of prescriptions written for Vascepa are for the REDUCE IT indications (individuals with known CAD or those with Diabetes and two risk factors on statins with trigs > 150 ), meaning it is being utilized to prevent cardiovascular disease. You cannot substitute Lovaza or generic lovaza for these prescriptions - they have NO indication for this and you may actually be harming the patient by increasing their LDL by 49% - Lovaza and Vascepa are DIFFERENT medications and are NOT Interchangeable.
Furthermore if a prescription is written for Vascepa for REDUCE IT indications (95% of use) you cannot substitute generic Vascepa – this is direct patent infringement and law suits are have been filed for such ( Healthnet). Generic Vascepa is ONLY approved for trigs >500 it is NOT approved for reduction of cardiovascular risk and doing so will expose you to liability for direct patent infringement.
In summary:
Omega 3's that can be used for Trigs >500
Lovaza – Generic Lovaza - Vascepa - Generic Vascepa
Omega 3's that can be utilized for cardiovascular risk Reduction
VASCEPA
Recent AMRN News
- Form 8-K - Current report • Edgar (US Regulatory) • 06/04/2024 11:30:10 AM
- Amarin Board of Directors Announces CEO Transition • GlobeNewswire Inc. • 06/04/2024 11:30:00 AM
- Amarin Receives National Reimbursement for VAZKEPA® (icosapent ethyl) in Greece and Announces Exclusive Marketing and Commercialization Agreement with Vianex S.A. • GlobeNewswire Inc. • 05/28/2024 12:15:23 PM
- Amarin to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference • GlobeNewswire Inc. • 05/06/2024 12:00:00 PM
- Amarin Reports First Quarter 2024 Business Update and Financial Results • GlobeNewswire Inc. • 05/01/2024 11:00:00 AM
- Amarin Applauds HealthyWomen’s Citizen’s Petition Urging FDA To Take Further Action On Fenofibrate Prescribing in Patients at Risk of Cardiovascular Event • GlobeNewswire Inc. • 04/24/2024 06:00:01 PM
- Amarin Announces Results of Annual General Meeting of Shareholders • GlobeNewswire Inc. • 04/22/2024 12:00:25 PM
- Amarin to Report First Quarter 2024 Financial Results and Host Conference Call on May 1, 2024 • GlobeNewswire Inc. • 04/15/2024 12:00:00 PM
- Amarin Highlights Key Data Providing Mechanistic Insights into Eicosapentaenoic Acid (EPA) at ACC.24 • GlobeNewswire Inc. • 04/08/2024 12:00:00 PM
- New REDUCE-IT® Analyses Show VASCEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups • PR Newswire (Canada) • 04/08/2024 10:30:00 AM
- New REDUCE-IT® Analyses Show VASCEPA®/VAZKEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups • GlobeNewswire Inc. • 04/06/2024 07:30:00 PM
- Amarin Provides Update on VAZKEPA® (Icosapent Ethyl) Intellectual Property Portfolio in Europe • GlobeNewswire Inc. • 04/03/2024 12:00:00 PM
- Research Evaluating Benefits of VASCEPA®/VAZKEPA® (icosapent ethyl) to be Presented at the American College of Cardiology’s (ACC) Annual Scientific Session & Expo • GlobeNewswire Inc. • 03/25/2024 12:00:00 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 03/04/2024 10:30:53 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 03/04/2024 01:00:24 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/29/2024 12:06:26 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/29/2024 12:05:56 PM
- Amarin Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update • GlobeNewswire Inc. • 02/29/2024 12:00:00 PM
- Amarin to Report Fourth Quarter and Full Year 2023 Financial Results and Host Conference on February 29, 2024 • GlobeNewswire Inc. • 02/15/2024 01:00:00 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 02/12/2024 01:00:24 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/09/2024 09:31:50 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/09/2024 09:30:28 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/09/2024 09:30:12 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/02/2024 09:30:24 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/02/2024 09:30:22 PM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM
North Bay Resources Announces Successful Flotation Cell Test at Bishop Gold Mill, Inyo County, California • NBRI • Jun 27, 2024 9:00 AM
Branded Legacy, Inc. and Hemp Emu Announce Strategic Partnership to Enhance CBD Product Manufacturing • BLEG • Jun 27, 2024 8:30 AM
POET Wins "Best Optical AI Solution" in 2024 AI Breakthrough Awards Program • POET • Jun 26, 2024 10:09 AM
HealthLynked Promotes Bill Crupi to Chief Operating Officer • HLYK • Jun 26, 2024 8:00 AM
Bantec's Howco Short Term Department of Defense Contract Wins Will Exceed $1,100,000 for the current Quarter • BANT • Jun 25, 2024 10:00 AM